Community Connect, an open-access space, is a valuable addition and important highlight of The Union World Conference of Lung Health 2024.

Programs aimed at eliminating tuberculosis have improved throughout the United States, with most indicating reductions in disease incidence and higher rates of treatment completion.

Bangladesh, being densely populated, with more than 1,000 people living per square kilometre, continues to be a challenging context for control of TB. The rise of antimicrobial resistance raises the bar.

A new consortium co-led by Weill Cornell Medicine has been awarded a five-year, $31 million grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to accelerate the development of faster, more effective treatment regimens for tuberculosis (TB).

An "unconventional" immune response now identified by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) is a potential new pathway for developing new vaccines for tuberculosis (TB), according to a new publication.

Although time to treatment discontinuation did not significantly differ between patients with latent tuberculosis on the basis of treatment regimen, interruptions in therapy varied by social and demographic factors.

Method for the detection of tuberculosis (TB) in children using modified FFP2 masks shows that children suffering from TB are unlikely to produce aerosols responsible for the transmission of this lung disease.

If there is one medical exam that everyone in the world has taken, it's a chest x-ray. Clinicians can use radiographs to tell if someone has tuberculosis, lung cancer, or other diseases, but they can't use them to tell if the lungs are functioning well.

For many years, the International Union Against Tuberculosis and Lung Disease (The Union) has pioneered capacity building in operational research. While there are many resources, a written, comprehensive guide has not been available.

• Tuberculosis (TB) makes 10 million people sick every year, and kills around 1.5 million people, more than any other infectious disease.  
• Drug resistant TB is a growing problem, with more than 400 thousand new cases annually, and more than 150 thousand deaths. 
• MTBVAC is a highly promising TB vaccine candidate that aims to prevent both drug sensitive and drug resistant TB in infants as well as in adolescents and adults.

O Porriño, 20th June 2024. Biofabri, a global human vaccine development company that is part of the Zendal group, and TBVI, a non-profit foundation facilitating the discovery and development of new TB vaccines that are globally accessible and affordable, have signed a contract with the European Health and Digital Executive Agency (HaDEA) under the EU4Health Programme to accelerate the final development of the MTBVAC vaccine. MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.